It has been discovered that suppressing the IL-6 gene expression in CAR-Ts significantly decreases the IL-6 release from monocytes and it also reduces the possibility of severe CRS and CRES without reducing the antitumor efficacy of CAR-Ts in vitro and in vivo (69, 70). Here, IL6 is linked to congenital rubella syndrome.